Contact - Signal12

Signal12 is bringing disruptive innovation to the field of ophthalmology. We are actively seeking to expand our pipeline of promising investigational therapies and welcome partnership inquiries.

Interested in partnering with us?

We’re looking for strategic investors who share our vision for revolutionizing ocular health. Whether you’re a venture capitalist, private equity firm, or an individual investor passionate about innovative healthcare solutions, we’d love to hear from you.

Please fill out the form below to get in touch with our investor relations team.

"*" indicates required fields

Pro-ocular
Clinical Trials
Company
Leadership

Signal12

Signal12 is clinical-stage dry eye company focused on the discovery, development, and commercialization of first-in-class therapies to address ophthalmic diseases. Its patented technology enables existing drugs to act through unique neural pathways.